GlassScriptPhysician profile
Wendy Vogel
NPI 1497748362
$2,755.93
in general payments reported to CMS, 2019-2025
20 companies · $78.46 in 2025
The $78.46 reported for 2025 was less than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $503 · 2022: $1,226 · 2023: $685 · 2024: $263 · 2025: $78.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $149 · Travel and Lodging: $92.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.44 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $148.70 |
| Travel and Lodging | $92.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $481.08 | 2021-2023 | Reblozyl |
| Janssen Biotech, INC. | $380.95 | 2022-2023 | Erleada, Rybrevant, Akeega |
| Lilly USA, LLC | $348.10 | 2021-2023 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $240.91 | 2024 | |
| Janssen Scientific Affairs, LLC | $167.52 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $157.28 | 2021-2022 | |
| Amgen INC. | $125.00 | 2023 | Lumakras |
| Seagen INC. | $124.48 | 2021-2022 | |
| Epizyme, INC. | $112.04 | 2021-2022 | |
| Gilead Sciences, INC. | $99.98 | 2022 | |
| Novocure INC. | $81.27 | 2021 | |
| Novartis Pharmaceuticals Corporation | $78.46 | 2025 | |
| Incyte Corporation | $76.18 | 2023 | Jakafi |
| Puma Biotechnology, INC. | $66.54 | 2023 | Nerlynx |
| Abbvie INC. | $60.02 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $55.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $37.92 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.50 | 2023 | |
| Celgene Corporation | $21.69 | 2024 | Reblozyl |
| Genzyme Corporation | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.